{"id":471249,"date":"2021-04-06T01:33:14","date_gmt":"2021-04-06T05:33:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471249"},"modified":"2021-04-06T01:33:14","modified_gmt":"2021-04-06T05:33:14","slug":"oxurion-nv-enters-into-a-capital-commitment-of-up-to-e30-million-with-negma-group","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oxurion-nv-enters-into-a-capital-commitment-of-up-to-e30-million-with-negma-group\/","title":{"rendered":"Oxurion NV enters into a Capital Commitment of up to \u20ac30 Million with Negma Group"},"content":{"rendered":"
\n

\n Leuven, BE, Boston, MA, US \u2013 April 6, 2021 \u2013 7.30 AM CET <\/strong>\u2013 Oxurion NV<\/a> (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today announces that is has agreed to a capital commitment of up to \u20ac30 Million with Negma Group.<\/p>\n

Negma Group is a Paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach.<\/p>\n

Negma Group has committed to subscribe to up to \u20ac30 million in equity in tranches over a 12-month period through mandatory convertible bonds at Oxurion\u2019s sole discretion.<\/p>\n

Oxurion anticipates initial clinical data from its lead drug candidate THR-149 later this year. THR-149 is a plasma kallikrein inhibitor being developed as a potential new standard of care for diabetic macular edema (DME) patients, who respond sub-optimally to anti-VEGF therapy. \u00a0<\/p>\n

Oxurion also expects to initiate a Phase 2 clinical trial with THR-687 in DME by mid-year. THR-687 is a pan-RGD integrin inhibitor that is being developed as a potential first line therapy for all DME patients. THR-687 also holds potential to deliver improved treatment outcomes for patients with wet Age-related Macular Degeneration (wet AMD) and Retinal Vein Occlusion (RVO).<\/p>\n

\n Patrik De Haes, M.D., CEO of Oxurion, says<\/strong>: \u201cI am happy that we have been able to agree on this flexible financing agreement, which is under our control and can be exercised at our discretion. Access to these funds will allow us to focus on progressing our two exciting novel and differentiated back of the eye drug candidates that are targeting potential market opportunities of over $12 billion, beyond key value inflection points in 2021 and 2022.\u201d<\/em><\/p>\n

\u201cWe are excited to collaborate with Oxurion. At <\/em>Negma Group, we invest in people and have been very impressed by both the scientific rigor and clinical experience of the Oxurion team. We are proud to partner with this team while they advance two very distinct and innovative programs that have great potential to deliver much improved clinical outcomes to patients suffering from debilitating retinal vascular disorders such as DME, wet AMD and RVO<\/em>\u201d, says Sophie Villedieu, Equity Capital Market Associate of Negma Group.<\/strong><\/p>\n

\n END<\/strong>\n <\/p>\n

\n For further information please contact:<\/strong>\n <\/p>\n\n\n
\n Oxurion NV<\/u>
\n
Wouter Piepers,
Global Head of Investor Relations
& Corporate Communications
Tel: +32 478 33 56 32
wouter.piepers@oxurion.com<\/a><\/p>\n

\u00a0<\/p>\n

Negma Group<\/u>
Anthony de Rauville, CIO
Tel\u00a0: +33 (0)6 48 10 16 41
anthony@negmagroup.com<\/a><\/p>\n

\u00a0<\/p>\n

Sophie Villedieu, ECM Associate
Tel: +33 (0)6 24 48 07 94
sophie@negmagroup.com<\/a><\/p>\n

\u00a0 <\/td>\n

\n EU <\/u>
\n
\n Citigate Dewe Rogerson <\/u>
\n
David Dible\/ Sylvie Berrebi\/Frazer Hall
Tel: +44 20 7638 9571
oxurion@citigatedewerogerson.com<\/a><\/p>\n

\u00a0<\/p>\n

US<\/u>
Westwicke, an ICR Company<\/u>
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com<\/a><\/td>\n<\/tr>\n<\/table>\n

\n
\u00a0<\/p>\n

\n About Oxurion <\/strong>\n <\/p>\n

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with Diabetic Macular Edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet Age-related Macular Degeneration (AMD) and Retinal Vein Occlusion (RVO). <\/p>\n

Oxurion is aiming to build the leading global franchise in the treatment of DME, based on the successful development of its two novel therapeutics:<\/p>\n